2013年版欧洲肝脏研究学会(EASL)丙型肝炎病毒感染管理临床实践指南解读

Interpretation of the 2013 EASL Clinical Practice Guidelines for Management of Hepatitis C Virus Infection

目的:两种蛋白酶抑制剂治疗基因1型丙型肝炎病毒(HCV)感染患者的Ⅲ期临床试验已经完成,并且在欧美等地区批准上市。欧洲肝脏研究学会(EASL)于2013年对HCV感染管理指南进行了修订更新。本文旨在对2013年版EASL丙型肝炎病毒感染管理临床实践指南进行部分解读。方法:从HCV治疗目标及终点、治疗适应证、不同基因分型HCV患者的治疗策略角度进行解读。结果与结论:聚乙二醇干扰素/利巴韦林(PegIFN/RBV)联合特拉泼维(TVR)或波赛泼维(BOC)是所批准的对基因1型HCV患者的标准治疗,PegIFN/RBV二联疗法仍然是非基因1型HCV患者的标准治疗。

Objective：Two protease inhibitors have completed phase Ⅲ trials in patients infected with HCV genotype 1,and have approved for use in Europe and elsewhere market.Therefore,European Association for the Study of the Liver （EASL） updated the Clinical Practice Guidelines （CPGs） for the management of hepatitis C virus infection recently.The article intends to interpret some sections of the CPGs.Methods：We interpreted the CGPS from the following aspects：treatment goal,indications and the different treatment strategies for patients with different genotypes.Results and Conclusion：The combination of pegylated interferon-α and ribavirin （PeglFN/RBV） and telaprevir （TVR） or boceprevir （BOC） is the approved standard treatment strategy for chronic hepatitis C genotype 1,and PeglFN/RBV dual therapy remains the standard treatment strategy for HCV patients with other genotypes.